Hi, today we are going to talk about Merck & Co. and its current landscape.
Merck & Co. shares are in evidence today as was unveiled that the company it's going to acquire ArQule for $20 per share in cash, totalizing a deal of $2.7 billion. In this season of Mergers and Acquisitions, the Merck & Co. move is based on its interest in pushing its already established leadership on the Cancer-Drug Race, since the company has the top-selling immunotherapy drug Keytruda, as the attention of the pharmaceutical over the sector growths.
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
Merck & Co. shares are in evidence today as was unveiled that the company it's going to acquire ArQule for $20 per share in cash, totalizing a deal of $2.7 billion. In this season of Mergers and Acquisitions, the Merck & Co. move is based on its interest in pushing its already established leadership on the Cancer-Drug Race, since the company has the top-selling immunotherapy drug Keytruda, as the attention of the pharmaceutical over the sector growths.
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
Igor Silva · análise técnica e sistemas quantitativos
▎ TraderLab — cursos, indicadores e execução com disciplina · traderlab.finfocus.com.br/
▎ TraderLab — cursos, indicadores e execução com disciplina · traderlab.finfocus.com.br/
免責聲明
這些資訊和出版物並非旨在提供，也不構成TradingView提供或認可的任何形式的財務、投資、交易或其他類型的建議或推薦。請閱讀使用條款以了解更多資訊。
Igor Silva · análise técnica e sistemas quantitativos
▎ TraderLab — cursos, indicadores e execução com disciplina · traderlab.finfocus.com.br/
▎ TraderLab — cursos, indicadores e execução com disciplina · traderlab.finfocus.com.br/
免責聲明
這些資訊和出版物並非旨在提供，也不構成TradingView提供或認可的任何形式的財務、投資、交易或其他類型的建議或推薦。請閱讀使用條款以了解更多資訊。